Navigation Links
Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products
Date:6/8/2011

EAST BRUNSWICK, N.J. and EDISON, N.J., June 8, 2011 /PRNewswire/ -- Amerigen Pharmaceuticals Limited and AustarPharma, LLC today announced they had entered into a broad-based collaboration agreement regarding the development of generic oral controlled release products. Under the terms of the agreement, AustarPharma will use its proprietary technologies to develop and manufacture products for Amerigen to commercialize in the United States and other territories. AustarPharma received an up-front fee and is eligible for additional product specific development milestones, plus manufacturing revenues and royalties on any commercialized products.

"This collaboration allows Amerigen to augment its internal product development activities and accelerate the company's efforts to build a portfolio of differentiated, high value generic pharmaceuticals," said Jonathan Embleton, Chief Business Officer for Amerigen. "We look forward to working with AustarPharma to complete the development and file for approval for some technically very challenging products."

President & CEO of AustarPharma, Dr Ron Liu commented, "As a technology based company, AustarPharma focuses on developing high technology barrier products. The combination of Amerigen's development, regulatory and commercial capabilities and AustarPharma's advanced controlled-release technologies in generic drug development will greatly benefit both companies. We highly value this collaboration."

About Amerigen

Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in East Brunswick, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese SFDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.

About AustarPharma

AustarPharma is a technology based pharmaceutical company based in Edison NJ, USA. The core competencies of the company are advanced drug delivery technologies. The key established platform technologies include several controlled-release technologies, such as osmotic pump extended-release technology, and many solubilization technologies used to enhance bioavailability and reduce bio-variability of water-insoluble drugs.  AustarPharma has taken advantages of these platform technologies to collaborate with multiple companies in the US and overseas to develop high technology barrier products. With the acquisition of Abbott's cGMP commercial manufacturing and testing facility at Edison, NJ in 2009, AustarPharma is now able to develop a drug product from very beginning in laboratories all the way to commercialization in the US and worldwide markets.


'/>"/>
SOURCE Amerigen Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... , May 30, 2016 ... reach USD 7.3 billion by 2024, according to ... The increasing natality rate, the growing malnutrition coupled ... cancer and gastro-intestinal tract diseases are expected to ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ...
(Date:5/30/2016)... LifeScienceIndustryResearch.com adds "Ulcerative Colitis ... with comprehensive information on the therapeutic development for ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Ulcerative Colitis ...
(Date:5/27/2016)... LabStyle Innovations Corp . ( ... today announced that the Company,s Chief Financial Officer, Zvi ... held June 1-2 in New York, NY ... in Los Angeles, CA. ... operational milestones, including the U.S. FDA Clearance and commercial launch ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... firm and statement solutions provider, for the tenth consecutive year as a ... issue of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing ...
(Date:5/31/2016)... ... May 31, 2016 , ... CURE ... patients with cancer, has added Cancer and Careers to its ... timely content on continuing successful careers while fighting cancer. , As partners, both ...
(Date:5/30/2016)... ... ... As the CDC relaxes its stance on traditional No-Nit policies, parents wonder what ... free. , According to a May 26 article from news source KHON2 ... despite the fact that they may be harboring an infestation. Previous No-Nit policies stated ...
(Date:5/30/2016)... ... May 30, 2016 , ... Zane Benefits, the leader ... an original infographic, " Health Benefits Reimbursement Compliance Timeline ." , The ... complies with various federal regulations and reforms. , Navigating the new health reforms ...
(Date:5/30/2016)... ... May 30, 2016 , ... Another ER facility operated ... Plano, located at 3960 Legacy Drive, Plano, TX and is open 24 hours daily. ... Commerce followed by a medical open house. The Jasper High School band entertained attendees ...
Breaking Medicine News(10 mins):